Regeneron Net Working Capital from 2010 to 2024

REGN Stock  USD 978.52  10.54  1.09%   
Regeneron Pharmaceuticals Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 11.2 B. During the period from 2010 to 2024, Regeneron Pharmaceuticals Net Working Capital quarterly data regression pattern had sample variance of 30929674.4 T and median of  3,199,547,000. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
16.1 B
Current Value
11.2 B
Quarterly Volatility
5.6 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Regeneron Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regeneron main balance sheet or income statement drivers, such as Depreciation And Amortization of 442.1 M, Interest Expense of 76.7 M or Total Revenue of 13.8 B, as well as many exotic indicators such as Price To Sales Ratio of 6.79, Dividend Yield of 0.0 or PTB Ratio of 5.22. Regeneron financial statements analysis is a perfect complement when working with Regeneron Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Regeneron Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Regeneron Pharmaceuticals Technical models . Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Latest Regeneron Pharmaceuticals' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Regeneron Pharmaceuticals over the last few years. It is Regeneron Pharmaceuticals' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regeneron Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Regeneron Net Working Capital Regression Statistics

Arithmetic Mean7,008,793,559
Geometric Mean5,469,502,281
Coefficient Of Variation79.35
Mean Deviation4,519,234,612
Median3,199,547,000
Standard Deviation5,561,445,347
Sample Variance30929674.4T
Range14.3B
R-Value0.80
Mean Square Error11987135.9T
R-Squared0.64
Significance0.0003
Slope994,956,342
Total Sum of Squares433015440.9T

Regeneron Net Working Capital History

202411.2 B
202316.1 B
202217.5 B
202117.1 B
20207.1 B
20195.6 B
2018B

About Regeneron Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Regeneron Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Regeneron Pharmaceuticals investors use historical funamental indicators, such as Regeneron Pharmaceuticals's Net Working Capital, to determine how well the company is positioned to perform in the future. Although Regeneron Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Regeneron Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Regeneron Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Regeneron Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Regeneron Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital16.1 B11.2 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out the analysis of Regeneron Pharmaceuticals Correlation against competitors.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Stocks Directory
Find actively traded stocks across global markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Earnings Share
33.85
Revenue Per Share
122.574
Quarterly Revenue Growth
(0.01)
Return On Assets
0.0774
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.